Eli Lilly and Stock Forecast for 2022 - 2025 - 2030

Updated on 09/26/2022

Stock Rating
16
Price Target
$350.00
Consensus
Outperform
Upside
12.37%
Analysts
12
Stock Rating
16
Upside
12.37%
Analysts
12
Price Target
$350.00

Eli Lilly and Stock Forecast and Price Target

Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $350.00. If it reached this goal, it would represent a potential upside of approximately 12.37% from the previous closing price in September, 2022. The high end is $412.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$350.00

12.37% Upside

Outperform
Outperform

Eli Lilly and 2022 - 2025 - 2030 için Gerçeğe Uygun Değer Tahmini

Eli Lilly and's Price has seen growth In the last three years, going from $118.22 to $173.81 – a gain of 47.03% In the next year, analysts believe that Fair Value will reach $184.67 – an increase of 6.25%. For the next nine years, the forecast is forFair Value to grow by 148.04%.

2022 Gerçeğe Uygun Değer Tahmin
$184.67
2023 Gerçeğe Uygun Değer Tahmin
$205.97
2024 Gerçeğe Uygun Değer Tahmin
$250.06
2025 Gerçeğe Uygun Değer Tahmin
$302.89
2026 Gerçeğe Uygun Değer Tahmin
$342.72
2027 Gerçeğe Uygun Değer Tahmin
$362.53
2028 Gerçeğe Uygun Değer Tahmin
$395.97
2029 Gerçeğe Uygun Değer Tahmin
$413.01
2030 Gerçeğe Uygun Değer Tahmin
$431.11
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 12
$166.72 $185.23 9.17%
ROG Stock Forecast Roche Holding Outperform 18
CHF309.30 CHF384.23 21.24%
ABBV Stock Forecast AbbVie Outperform 9
$143.06 $164.23 9.05%
MRK Stock Forecast Merck Outperform 6
$86.78 $99.57 15.23%
TMO Stock Forecast Thermo Fisher Scientific Outperform 18
$520.79 $658.24 29.61%

Eli Lilly and 2022 - 2025 - 2030 Gelir Tahmini

Eli Lilly and's Revenue has seen growth In the last three years, going from $21.49B to $28.32B – a gain of 31.75% In the next year, analysts believe that Revenue will reach $28.51B – an increase of 0.66%. For the next nine years, the forecast is forRevenue to grow by 69.31%.

2022 Gelir Tahmini
$28.51B
2023 Gelir Tahmini
$30.45B
2024 Gelir Tahmini
$34.27B
2025 Gelir Tahmini
$38.90B
2026 Gelir Tahmini
$42.26B
2027 Gelir Tahmini
$43.57B
2028 Gelir Tahmini
$45.83B
2029 Gelir Tahmini
$47.19B
2030 Gelir Tahmini
$47.95B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ABT Stock Forecast Abbott Laboratories Outperform 14
$100.68 $128.88 25.15%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£100.16 £136.08 42.14%
NOVN Stock Forecast Novartis Hold 18
CHF74.36 CHF103.75 21.68%

Hisse Başına Temettü Tahmini 2022 - 2025 - 2030

In the last three years, Dividend per Share for Eli Lilly and has grown by 51.11%, going from $2.25 to $3.40. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $3.78 – an increase of 11.18%. Over the next nine years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 252.65%.

2022 DPS Tahmini
$3.78
2023 DPS Tahmini
$4.20
2024 DPS Tahmini
$4.68
2025 DPS Tahmini
$5.34
2026 DPS Tahmini
$5.47
2027 DPS Tahmini
$7.88
2028 DPS Tahmini
$9.07
2029 DPS Tahmini
$10.43
2030 DPS Tahmini
$11.99
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$70.71 $79.05 17.38%
AMGN Stock Forecast Amgen Hold 9
$226.97 $246.51 12.35%
SAN Stock Forecast Sanofi Outperform 18
78.81€ 104.66€ 40.21%

Eli Lilly and 2022 - 2025 - 2030 için Serbest Nakit Akışı Tahmini

In the last three years, Eli Lilly and's Free Cash Flow has increased by 37.95%, going from $4.31B to $5.95B. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $7.76B – an increase of 30.41%. The Eli Lilly and forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.

2022 FCF Tahmini
$7.76B
2023 FCF Tahmini
$8.00B
2024 FCF Tahmini
$9.32B
2025 FCF Tahmini
$10.94B
2026 FCF Tahmini
$12.77B
2027 FCF Tahmini
$14.28B
2028 FCF Tahmini
$14.82B
2029 FCF Tahmini
$15.14B
2030 FCF Tahmini
$15.12B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CSL Stock Forecast CSL Outperform 16
$278.14 $228.01 -19.88%
GILD Stock Forecast Gilead Sciences Outperform 11
$62.86 $69.65 12.95%
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 2
$697.33 $696.64 8.70%

Eli Lilly and 2022 - 2025 - 2030 için Net Gelir Tahmini

Eli Lilly and's Net Income has grown in the last three years, jumping from $3.23B to $5.58B – an increase of 72.70%. In the next year, analysts predict that Net Income will reach $7.88B – an increase of 41.25%. For the next nine years, the forecast is for Net Income to grow by 211.18%.

2022 NI Tahmini
$7.88B
2023 NI Tahmini
$8.82B
2024 NI Tahmini
$10.57B
2025 NI Tahmini
$12.76B
2026 NI Tahmini
$13.95B
2027 NI Tahmini
$15.07B
2028 NI Tahmini
$16.01B
2029 NI Tahmini
$16.68B
2030 NI Tahmini
$17.37B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ZTS Stock Forecast Zoetis Outperform 18
$150.05 $235.45 49.95%
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 18
159.00€ 147.51€ 32.08%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$233.92 $278.08 19.70%

Eli Lilly and 2022 - 2025 - 2030 için FAVÖK Tahmini

In the last three years, Eli Lilly and's EBITDA has grown, increasing from $7.63B to $9.73B – an increase of 27.38%. For next year, the 12 analysts predict EBITDA of $10.44B, which would mean an increase of 7.30%. Over the next nine years, the pros' prediction is EBITDAof $20.45B, which would mean a nine-year growth forecast of 110.29%.

2022 FAVÖK Tahmini
$10.44B
2023 FAVÖK Tahmini
$11.82B
2024 FAVÖK Tahmini
$14.01B
2025 FAVÖK Tahmini
$17.51B
2026 FAVÖK Tahmini
$16.01B
2027 FAVÖK Tahmini
$17.17B
2028 FAVÖK Tahmini
$17.93B
2029 FAVÖK Tahmini
$18.95B
2030 FAVÖK Tahmini
$20.45B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GSK Stock Forecast GSK Outperform 16
£13.13 £16.08 43.95%
BAYN Stock Forecast Bayer Outperform 7
49.58€ 67.79€ 60.35%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥3.79k ¥0.00 16.13%

2022 - 2025 - 2030 için FVÖK Tahmini

Eli Lilly and's EBIT has increased by 35.71% In the last three years, going from $6.03B to $8.18B. In the next year, analysts expect EBIT to reach $9.13B – an increase of 11.70%. For the next nine years, the forecast is for EBIT to grow by 143.31%.

2022 FVÖK Tahmini
$9.13B
2023 FVÖK Tahmini
$10.24B
2024 FVÖK Tahmini
$12.44B
2025 FVÖK Tahmini
$15.21B
2026 FVÖK Tahmini
$16.48B
2027 FVÖK Tahmini
$18.00B
2028 FVÖK Tahmini
$19.05B
2029 FVÖK Tahmini
$19.75B
2030 FVÖK Tahmini
$19.90B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.40k ¥0.00 32.24%
BIIB Stock Forecast Biogen Outperform 11
$197.78 $242.78 15.03%
BAX Stock Forecast Baxter International Outperform 17
$55.41 $69.92 24.53%

Eli Lilly and EPS Fiyat Tahmini 2022 - 2025 - 2030 yılları arası tahmini

Eli Lilly and's EPS has seen growth In the last three years, going from $5.55 to $8.16 – a gain of 47.03% In the next year, analysts believe that EPS will reach $8.67 – an increase of 6.25%. For the next nine years, the forecast is forEPS to grow by 148.04%.

2022 EPS Tahmini
$8.67
2023 EPS Tahmini
$9.67
2024 EPS Tahmini
$11.74
2025 EPS Tahmini
$14.22
2026 EPS Tahmini
$16.09
2027 EPS Tahmini
$17.02
2028 EPS Tahmini
$18.59
2029 EPS Tahmini
$19.39
2030 EPS Tahmini
$20.24
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.90k ¥0.00 26.02%
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$200.78 $209.00 19.28%
4507 Stock Forecast Shionogi & Outperform 18
¥6.85k ¥0.00 28.18%